Delivery Order SPE2DB22D2211-SPE2DB25FSERL
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of HUMIRA Pen 40 mg/0.8 mL, a pharmaceutical product used in treating autoimmune conditions. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $1,156.39 and is scheduled for completion by September 5, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL with a ceiling value of $1,185.69. This is a firm fixed price delivery order under a non-set-aside competitive procurement. The contract is set to be completed by August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $5,330.07 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a injectable medication used to treat autoimmune conditions. The contract, with an ultimate completion date of September 10, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. This award was made on a competitive basis with no...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,398.85 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL on September 9, 2025, with an ultimate completion date of September 10, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,265.90 delivery order on July 18, 2025, for HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 21, 2025. This competitive award, issued under firm fixed pricing with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL medication. This is a firm fixed-price delivery order valued at $33,364.14, with an ultimate completion date of July 22, 2025. The award carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a $3,828.03 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL pharmaceutical supplies on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The supplies will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on July 28, 2025, with a ceiling value of $2,265.90 and an ultimate completion date of July 29, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, which is AmerisourceBergen's headquarters location. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a $9,400.49 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 29, 2025, with an ultimate completion date of July 30, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The contractor will perform work at its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $1,888.25 delivery order contract to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with an ultimate completion date of August 5, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSERLDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $13,867.05 on September 10, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL units. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under DLA's pharmaceutical procurement processes. The contract calls for performance through September 11, 2025, with delivery to AmerisourceBergen's distribution facility in Conshohocken, Pennsylvania. As a child delivery order, this award leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive federal contract portfolio demonstrates consistent capability to meet DLA requirements through open competition, with previous delivery orders covering diverse therapeutic domains including specialty medications, vaccines, and medical devices. This HUMIRA award reflects the ongoing demand for immunosuppressive biologics within military healthcare supply chains, with the transaction executed as a firm fixed-price delivery order under the company's established pharmaceutical prime vendor agreement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.9k | 9/10/25 |